Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian

About this update from Defence Therapeutics Inc Class A

Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)  ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today from the Board of Directors of Defence to deepen engagement with the Company by joining the Scientific Advisory Board ("SAB"). Defence Therapeutics' current SAB is composed of Rob Leanna, PhD, Danny Chui, PhD and Brendan Hussey, PhD. The addition of Dr. Sarkis Meterissian, who is the Director of the Breast Center of the McGill University Health Centre ("MUHC") and the Head of the MUHC Breast Tumor Site Group, will strengthen the SAB by bringing direct expertise in the drugs and an acute understanding of patients needs. "I would like to thank Dr. Sarkis Meterissian for his five years on the Board of Directors. I am confident that his contribution to the SAB will be significant to Defence's success. Sarkis has been a strong believer in Defence's ACCUM® platform since day one, and now more than ever he wants to be more deeply involved in bringing it to the clinics for the benefit of patients," said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics. In addition, the Company wishes to announce that it has granted 150,000 incentive stock options to employees and consultants of the Company, in accordance with the terms and conditions of Defence's omnibus incentive plan. The options are vested immediately and exercisable at a price of 58 cents per share for a period of five years from the date of grant. About Defence Therapeutics: Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursuing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to the patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencethe...

View stock analysis, news, and events for Defence Therapeutics Inc Class A